Literature DB >> 31202430

Who is the best donor for haploidentical stem cell transplantation?

Piyanuch Kongtim1, Stefan O Ciurea2.   

Abstract

Recent advances in haploidentical stem cell transplantation have enabled the use of human leukocyte antigen-half matched related donors for allogeneic stem cell transplantation and helped overcome one of the most important limitation in transplantation, which is donor availability, especially for the non-Caucasian population and mixed race individuals, extending allogeneic stem cell transplant for almost all patients in need. As many multiple potential related donors may now be available, it is increasingly clear that not all of these donors can provide equivalent transplant outcomes. Here we review the current available evidence of donor characteristics known to be associated with transplant outcomes for different types of haploidentical transplants using unmanipulated grafts (with post-transplant cyclophosphamide-based graft-vs-host prophylaxis and G-CSF and anti-thymocyte globulin approach) as well as modified grafts (with either selective or complete T-cell depletion). While various platforms use haploidentical donors, graft manipulation and approach to prevent graft-vs-host post-transplant may impact on donor selection and transplant outcomes.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Donor-specific anti-HLA antibodies; Haploidentical stem cell transplantation; NK cell alloreactivity; Noninherited maternal antigens; Noninherited paternal antigen

Mesh:

Substances:

Year:  2018        PMID: 31202430     DOI: 10.1053/j.seminhematol.2018.08.003

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  4 in total

1.  A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation.

Authors:  Meng-Zhu Shen; Shen-Da Hong; Rui Lou; Rui-Ze Chen; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Exp Hematol Oncol       Date:  2022-05-03

2.  Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies.

Authors:  Fei-Fei Tang; Xiang-Yu Zhao; Ming-Rui Huo; Ying-Jun Chang; Wei Han; Yu-Hong Chen; Chen-Hua Yan; Lan-Ping Xu; Xiao-Hui Zhang; Xiao-Jun Huang; Yu Wang
Journal:  Bone Marrow Transplant       Date:  2021-07-08       Impact factor: 5.483

3.  Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.

Authors:  Jukka Partanen; Kati Hyvärinen; Heike Bickeböller; Katarzyna Bogunia-Kubik; Rachel E Crossland; Milena Ivanova; Francesca Perutelli; Ralf Dressel
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561

4.  Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches.

Authors:  Matteo Tanzi; Michela Consonni; Michela Falco; Federica Ferulli; Enrica Montini; Annamaria Pasi; Rosalia Cacciatore; Silvia Brugnatelli; Paolo Pedrazzoli; Marco Zecca; Stella Boghen; Paolo Dellabona; Giulia Casorati; Daniela Montagna
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.